Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics
Prostate cancer diagnostics are rapidly advancing through innovations in nanotechnology, biosensing strategies, and molecular recognition. This review analyzes studies focusing on quantum dot (QD)-based biosensors for detecting prostate cancer biomarkers with high sensitivity and specificity. It cov...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Nanomaterials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-4991/15/15/1162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849770583444684800 |
|---|---|
| author | Hossein Omidian Erma J. Gill Luigi X. Cubeddu |
| author_facet | Hossein Omidian Erma J. Gill Luigi X. Cubeddu |
| author_sort | Hossein Omidian |
| collection | DOAJ |
| description | Prostate cancer diagnostics are rapidly advancing through innovations in nanotechnology, biosensing strategies, and molecular recognition. This review analyzes studies focusing on quantum dot (QD)-based biosensors for detecting prostate cancer biomarkers with high sensitivity and specificity. It covers diverse sensing platforms and signal transduction mechanisms, emphasizing the influence of the QD composition, surface functionalization, and bio interface engineering on analytical performance. Key metrics such as detection limits, dynamic range, and compatibility with biological samples, including serum, urine, and tissue, are critically assessed. Recent advances in green-synthesized QDs and smartphone-integrated diagnostic platforms are highlighted, including lateral flow assays, paper-based devices, and pH-responsive hydrogels for real-time, low-cost, and decentralized cancer screening. These innovations enable multiplexed biomarker detection and tumor microenvironment monitoring in point-of-care settings. This review concludes by addressing the current limitations, scalability challenges, and future research directions for translating QD-enabled biosensors into clinically viable diagnostic tools. |
| format | Article |
| id | doaj-art-d0dc684cbbc4475595e1f9faf5282fd9 |
| institution | DOAJ |
| issn | 2079-4991 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nanomaterials |
| spelling | doaj-art-d0dc684cbbc4475595e1f9faf5282fd92025-08-20T03:02:56ZengMDPI AGNanomaterials2079-49912025-07-011515116210.3390/nano15151162Quantum Dot-Enabled Biosensing for Prostate Cancer DiagnosticsHossein Omidian0Erma J. Gill1Luigi X. Cubeddu2Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USABarry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USABarry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USAProstate cancer diagnostics are rapidly advancing through innovations in nanotechnology, biosensing strategies, and molecular recognition. This review analyzes studies focusing on quantum dot (QD)-based biosensors for detecting prostate cancer biomarkers with high sensitivity and specificity. It covers diverse sensing platforms and signal transduction mechanisms, emphasizing the influence of the QD composition, surface functionalization, and bio interface engineering on analytical performance. Key metrics such as detection limits, dynamic range, and compatibility with biological samples, including serum, urine, and tissue, are critically assessed. Recent advances in green-synthesized QDs and smartphone-integrated diagnostic platforms are highlighted, including lateral flow assays, paper-based devices, and pH-responsive hydrogels for real-time, low-cost, and decentralized cancer screening. These innovations enable multiplexed biomarker detection and tumor microenvironment monitoring in point-of-care settings. This review concludes by addressing the current limitations, scalability challenges, and future research directions for translating QD-enabled biosensors into clinically viable diagnostic tools.https://www.mdpi.com/2079-4991/15/15/1162quantum dotsprostate-specific antigen (PSA)biosensorsmultiplex diagnosticsnanomaterials |
| spellingShingle | Hossein Omidian Erma J. Gill Luigi X. Cubeddu Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics Nanomaterials quantum dots prostate-specific antigen (PSA) biosensors multiplex diagnostics nanomaterials |
| title | Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics |
| title_full | Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics |
| title_fullStr | Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics |
| title_full_unstemmed | Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics |
| title_short | Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics |
| title_sort | quantum dot enabled biosensing for prostate cancer diagnostics |
| topic | quantum dots prostate-specific antigen (PSA) biosensors multiplex diagnostics nanomaterials |
| url | https://www.mdpi.com/2079-4991/15/15/1162 |
| work_keys_str_mv | AT hosseinomidian quantumdotenabledbiosensingforprostatecancerdiagnostics AT ermajgill quantumdotenabledbiosensingforprostatecancerdiagnostics AT luigixcubeddu quantumdotenabledbiosensingforprostatecancerdiagnostics |